Compare · LQDA vs UTHR
LQDA vs UTHR
Side-by-side comparison of Liquidia Corporation (LQDA) and United Therapeutics Corporation (UTHR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LQDA and UTHR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- UTHR is the larger of the two at $22.74B, about 3.2x LQDA ($7.11B).
- UTHR has been more active in the news (44 items in the past 4 weeks vs 13 for LQDA).
- UTHR has more recent analyst coverage (20 ratings vs 17 for LQDA).
- Company
- Liquidia Corporation
- United Therapeutics Corporation
- Price
- -
- -
- Market cap
- $7.11B
- $22.74B
- 1M return
- -
- -2.27%
- 1Y return
- -
- +83.54%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 1999
- News (4w)
- 13
- 44
- Recent ratings
- 17
- 20
Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include LIQ861, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension; and LIQ865, a sustained-release formulation of bupivacaine for the treatment of local post-operative pain. The company also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Latest LQDA
- Chief Human Resource Officer Krepp Sarah converted options into 3,179 shares and sold $562,361 worth of shares (7,864 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 117,178 units (SEC Form 4)
- Chief Development Officer Khindri Sanjeev sold $84,740 worth of shares (1,185 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 65,947 units (SEC Form 4)
- CFO and COO Kaseta Michael converted options into 12,879 shares and sold $1,460,965 worth of shares (20,430 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 345,805 units (SEC Form 4)
- Chief Executive Officer Jeffs Roger sold $2,520,683 worth of shares (35,249 units at $71.51) as part of a pre-agreed trading plan and converted options into 28,167 shares, decreasing direct ownership by 0.62% to 1,130,426 units (SEC Form 4)
- Chief Business Officer Adair Jason converted options into 10,251 shares and sold $562,289 worth of shares (7,863 units at $71.51) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 217,126 units (SEC Form 4)
- General Counsel Schundler Russell converted options into 10,168 shares and sold $1,053,926 worth of shares (14,738 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 0.75% to 605,962 units (SEC Form 4)
- Chief Medical Officer Saggar Rajeev converted options into 8,018 shares and sold $709,816 worth of shares (9,926 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 171,799 units (SEC Form 4)
- Chief Commercial Officer Moomaw Scott converted options into 7,466 shares and sold $682,142 worth of shares (9,539 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 182,485 units (SEC Form 4)
- Chief Accounting Officer Boyle Dana converted options into 3,179 shares and sold $643,740 worth of shares (9,002 units at $71.51) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 169,519 units (SEC Form 4)
- Director Bloch Stephen M sold $6,051,170 worth of shares (75,000 units at $80.68) (SEC Form 4)
Latest UTHR
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,043,689 worth of shares (9,500 units at $530.91) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A exercised 9,500 shares at a strike of $135.42 and sold $5,038,340 worth of shares (9,500 units at $530.35) as part of a pre-agreed trading plan (SEC Form 4)
- EVP & GENERAL COUNSEL Mahon Paul A exercised 8,300 shares at a strike of $146.03 and sold $4,429,638 worth of shares (8,300 units at $533.69) as part of a pre-agreed trading plan (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A sold $5,004,909 worth of shares (9,500 units at $526.83) as part of a pre-agreed trading plan and exercised 9,500 shares at a strike of $135.42 (SEC Form 4)
- Chairperson & CEO Rothblatt Martine A sold $5,091,949 worth of shares (9,500 units at $535.99) as part of a pre-agreed trading plan and exercised 9,500 shares at a strike of $135.42 (SEC Form 4)
- Director Giltner Richard converted options into 1,310 shares, increasing direct ownership by 6% to 21,884 units (SEC Form 4)
- Director Kurzweil Ray converted options into 650 shares, increasing direct ownership by 5% to 13,320 units (SEC Form 4)
- Director Mesa Nilda converted options into 650 shares, increasing direct ownership by 13% to 5,678 units (SEC Form 4)
- Director Olian Judy D. converted options into 1,310 shares, increasing direct ownership by 31% to 5,555 units (SEC Form 4)
- Director Patusky Christopher converted options into 650 shares, increasing direct ownership by 44% to 2,140 units (SEC Form 4)